Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

PHASE3CompletedINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Type2diabetes
Interventions
DRUG

Insulin Glargine 100 UNT/ML Pen Injector [Lantus]

Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.

DRUG

Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg

Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg

DRUG

Pioglitazone 30mg

Pioglitazone 30mg

Trial Locations (1)

61001

Faiha Specialized Diabetes, Endocrine, and Metabolism Center, Basra

All Listed Sponsors
lead

University of Basrah

OTHER

NCT06107153 - Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control | Biotech Hunter | Biotech Hunter